Abstract:Viruses are the most common etiological agents of myocardium inflammation. Today the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) causes a high incidence of myocarditis and pericarditis. As a hypothetical scenario, we present a clinical case of a patient who underwent viral myocarditis on the background of SARS in 2004, with recurrent myocarditis in ARVI, the last of which was initiated by SARS-CoV-2. A 61-year-old male patient, in 2004 contacted a representative of the People's Republic of China and after 4 days felt the symptoms of ARVI. Before the viral disease, he had excellent health, the absence of cardiovascular diseases and pathological heredity. Fever 38–39 °C, myalgia, headache, general malaise, dry obsessive cough persisted for a week. After the addition of shortness of breath, he was hospitalized. According to the data of X-ray and computed tomography, infiltrates of the lungs of both of the "frosted glass" type were revealed. According to the clinic and laboratory data, a diagnosis of severe “atypical viral pneumonia” was made, and a diagnosis of viral myocarditis was suggested. Echocardiography showed a decrease in the left ventricular ejection fraction up to 50% for the first time, without signs of coronary heart disease based on the results of further examination. Dry cough disturbed in the next 4 months, LVEF 48–50% and 1 functional class of heart failure persisted for 10 years. The patient had a flu with mild respiratory symptoms in 2015, but it triggered a recurrence of myocarditis. The examination revealed a decrease in LVEF up to 35%, the progression of dilatation of the heart cavities also without signs of coronary heart disease according to the results of the treadmill test and coronary angiography. Post-inflammatory cardiopathy progressed relatively quickly during the year. The minimum LVEF was 23%; a cardioverter-defibrillator was implanted for secondary indications; radiofrequency ablation of fascicular tachycardia was performed. It was followed by another period of stabilization: 2 functional class of heart failure, ICD shocks did not occur. The patient underwent COVID-19 with minimal respiratory symptoms in March 2021. It provoked another recurrence of myocarditis, diagnosed with an increase in troponin, cerebral natriuretic peptide, CRP, ESR and increasing heart failure during 3 months. Persistent paroxysms of atrial fibrillation with a decrease of LVEF 15% and anasarсa. A successful radiofrequency isolation of the pulmonary vein was performed in 2021. By November 2021, in the absence of paroxysms, it was possible to achieve compensation for heart failure up to class 1 according to Vasilenko–Strazhesko and NYHA, LVEF 28%. In order to understand the recurrent nature of myocarditis against the background of various respiratory viral infections, an analysis of the literature was carried out, including the described cases of myocardial inflammation against the background of the predecessors of the SARS-CoV-2 strain: SARS-CoV-1 and MERS. We also reviewed the data on the diagnosis of viral myocarditis in the realities of this pandemic. It reveals a large heterogeneity of signs of inflammation of the heart muscle according to different diagnostic methods and large interobserver variability, and challenges us about the need to revise the criteria for myocarditis in the case of COVID-19.

Recurrent course of post-inflammatory cardiopathy: lessons from past epidemics

Chronic biopsy proven post-COVID myoendocarditis with SARS-Cov-2 persistence and high level of antiheart antibodies

COVID-19, Myocarditis and Pericarditis

Myocarditis - A silent killer in athletes: Comparative analysis on the evidence before and after COVID-19 pandemic

Post-COVID Myocarditis in Patients with Primary Cardiomyopathies: Diagnosis, Clinical Course and Outcomes

SARS-CoV-2 induced myocarditis: Current knowledge about its molecular and pathophysiological mechanisms

Fulminant Myocarditis with SARS-CoV-2 Infection: A Narrative Review from the Case Studies

COVID-19 myocarditis and prospective heart failure burden

Myocardial Oedema as a Consequence of Viral Infection and Persistence—A Narrative Review with Focus on COVID-19 and Post COVID Sequelae

Complete recovery after fulminant myocarditis in a patient with COVID-19

Recovery of a critically ill patient with COVID-19 myocarditis

Viral myocarditis: From molecular mechanisms to therapeutic prospects

Spectrum of Viral Pathogens Identified in Children with Clinical Myocarditis (Pre-Coronavirus Disease-2019, 2000-2018): Etiologic Agent Versus Innocent Bystander

Clinical outcome of established diagnostic and treatment modalities of COVID-19-associated myocarditis: a systematic review

Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era

COVID-19 AND CARDIOVASCULAR COMPLICATIONS. AN INAUSPICIOUS COMBINATION

The Influence of Diagnoses of Specific Viral Infections on In-Hospital Mortality, Length of Stay and Cost in Patients Admitted to Hospital with a Diagnosis of Myocarditis: An Analysis of the National Inpatient Sample

Post-acute sequelae of SARS-CoV-2 cardiovascular symptoms are associated with trace-level cytokines that affect cardiomyocyte function

Cardiac tamponade - an unexpected "long COVID-19" complication

Cardiovascular magnetic resonance evaluation of soldiers after recovery from symptomatic SARS-CoV-2 infection: a case–control study of cardiovascular post-acute sequelae of SARS-CoV-2 infection (CV PASC)

[SARS-CoV-2-induced non-bacterial endomyocarditis with the development of acquired heart defects]